A detailed history of O'Shaughnessy Asset Management, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, O'Shaughnessy Asset Management, LLC holds 3,566 shares of BPMC stock, worth $322,580. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,566
Previous 3,269 9.09%
Holding current value
$322,580
Previous $352,000 6.53%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$84.1 - $120.5 $24,977 - $35,788
297 Added 9.09%
3,566 $329,000
Q2 2024

Aug 14, 2024

BUY
$85.18 - $108.78 $25,383 - $32,416
298 Added 10.03%
3,269 $352,000
Q1 2024

May 13, 2024

BUY
$73.17 - $99.79 $41,926 - $57,179
573 Added 23.89%
2,971 $281,000
Q4 2023

Feb 09, 2024

BUY
$43.96 - $92.84 $105,416 - $222,630
2,398 New
2,398 $221,000
Q2 2022

Aug 11, 2022

SELL
$45.23 - $70.15 $190,599 - $295,612
-4,214 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$54.1 - $110.08 $649 - $1,320
-12 Reduced 0.28%
4,214 $269,000
Q4 2021

Feb 11, 2022

SELL
$94.25 - $115.99 $14,985 - $18,442
-159 Reduced 3.63%
4,226 $453,000
Q3 2021

Nov 10, 2021

BUY
$80.98 - $109.47 $69,480 - $93,925
858 Added 24.33%
4,385 $452,000
Q2 2021

Aug 09, 2021

SELL
$82.78 - $101.0 $2,897 - $3,535
-35 Reduced 0.98%
3,527 $310,000
Q1 2021

May 14, 2021

SELL
$90.71 - $108.28 $4,807 - $5,738
-53 Reduced 1.47%
3,562 $346,000
Q4 2020

Feb 11, 2021

BUY
$92.08 - $124.48 $332,869 - $449,995
3,615 New
3,615 $405,000
Q1 2020

May 13, 2020

SELL
$48.11 - $82.22 $2,646 - $4,522
-55 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$66.73 - $82.59 $3,670 - $4,542
55 New
55 $4,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track O'Shaughnessy Asset Management, LLC Portfolio

Follow O'Shaughnessy Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of O'Shaughnessy Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on O'Shaughnessy Asset Management, LLC with notifications on news.